The plasticity of primary microglia and their multifaceted effects on endogenous neural stem cells in vitro and in vivo.

Publisher: BioMed Central Country of Publication: England NLM ID: 101222974 Publication Model: Electronic Cited Medium: Internet ISSN: 1742-2094 (Electronic) Linking ISSN: 17422094 NLM ISO Abbreviation: J Neuroinflammation Subsets: MEDLINE

Original Publication: [London] : BioMed Central, c2004-

Microglia/*physiology ; Neural Stem Cells/*physiology; Animals ; Animals, Newborn ; Cell Differentiation/physiology ; Cell Movement/drug effects ; Cell Polarity/drug effects ; Cell Polarity/genetics ; Cell Proliferation/drug effects ; Cells, Cultured ; Cerebral Cortex/cytology ; Gene Expression Regulation/drug effects ; Gene Expression Regulation/physiology ; Interleukin-4/pharmacology ; Interleukin-6/metabolism ; L-Lactate Dehydrogenase/metabolism ; Lipopolysaccharides/pharmacology ; Male ; Microglia/drug effects ; Microglia/ultrastructure ; Neural Stem Cells/drug effects ; Nitric Oxide Synthase Type II/genetics ; Nitric Oxide Synthase Type II/metabolism ; Phagocytosis/physiology ; Rats ; Rats, Wistar ; Tumor Necrosis Factor-alpha/metabolism

Background: Microglia-the resident immune cells of the brain-are activated after brain lesions, e.g., cerebral ischemia, and polarize towards a classic "M1" pro-inflammatory or an alternative "M2" anti-inflammatory phenotype following characteristic temporo-spatial patterns, contributing either to secondary tissue damage or to regenerative responses. They closely interact with endogenous neural stem cells (NSCs) residing in distinct niches of the adult brain. The current study aimed at elucidating the dynamics of microglia polarization and their differential effects on NSC function.
Results: Primary rat microglia in vitro were polarized towards a M1 phenotype by LPS, or to a M2 phenotype by IL4, while simultaneous exposure to LPS plus IL4 resulted in a hybrid phenotype expressing both M1- and M2-characteristic markers. M2 microglia migrated less but exhibit higher phagocytic activity than M1 microglia. Defined mediators switched microglia from one polarization state to the other, a process more effective when transforming M2 microglia towards M1 than vice versa. Polarized microglia had differential effects on the differentiation potential of NSCs in vitro and in vivo, with M1 microglia promoting astrocytogenesis, while M2 microglia supported neurogenesis. Regardless of their polarization, microglia inhibited NSC proliferation, increased NSC migration, and accelerated NSC differentiation.
Conclusion: Overall, this study shed light on the complex conditions governing microglia polarization and the effects of differentially polarized microglia on critical functions of NSCs in vitro and in vivo. Refining the understanding of microglia activation and their modulatory effects on NSCs is likely to facilitate the development of innovative therapeutic concepts supporting the innate regenerative capacity of the brain.

Exp Transl Stroke Med. 2010 Dec 20;2(1):22. (PMID: 21171972)
Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15983-8. (PMID: 14668448)
Cell. 2010 Mar 19;140(6):918-34. (PMID: 20303880)
Immunity. 2010 Mar 26;32(3):317-28. (PMID: 20206554)
Neuroscience. 2015 Apr 30;292:71-80. (PMID: 25701708)
J Neurosci. 1999 Jul 15;19(14):5810-22. (PMID: 10407022)
J Neurosci. 2006 Mar 22;26(12):3182-91. (PMID: 16554469)
Curr Opin Neurol. 2005 Jun;18(3):315-21. (PMID: 15891419)
Trends Immunol. 2008 Aug;29(8):357-65. (PMID: 18599350)
Cell Tissue Res. 1974 May 8;148(4):477-91. (PMID: 4365458)
Physiol Rev. 2011 Oct;91(4):1281-304. (PMID: 22013212)
J Neuroinflammation. 2013 Mar 04;10:35. (PMID: 23452918)
Neuron. 2017 Sep 13;95(6):1246-1265. (PMID: 28910616)
Stroke. 2012 Nov;43(11):3063-70. (PMID: 22933588)
Nature. 2005 Jul 14;436(7048):266-71. (PMID: 16015332)
Glia. 2013 May;61(5):813-24. (PMID: 23404620)
Mol Cell Neurosci. 2006 Jan;31(1):149-60. (PMID: 16297637)
Pharmacol Ther. 2014 Jan;141(1):21-31. (PMID: 23954656)
J Neurosci. 2010 May 5;30(18):6454-60. (PMID: 20445071)
Glia. 1993 Jan;7(1):111-8. (PMID: 8423058)
Nat Neurosci. 2013 Dec;16(12):1896-905. (PMID: 24162652)
Expert Rev Neurother. 2011 Jun;11(6):783-6. (PMID: 21651326)
Nat Neurosci. 2012 Nov;15(11):1485-7. (PMID: 23086334)
J Neurosci Res. 2016 Feb;94(2):149-60. (PMID: 26525774)
Nat Rev Immunol. 2011 Oct 25;11(11):775-87. (PMID: 22025055)
J Neuroinflammation. 2017 Aug 22;14(1):166. (PMID: 28830445)
Cell. 2002 Aug 23;110(4):429-41. (PMID: 12202033)
Front Cell Neurosci. 2014 Aug 15;8:240. (PMID: 25177273)
Science. 2005 May 27;308(5726):1314-8. (PMID: 15831717)
Neural Plast. 2014;2014:610343. (PMID: 24772353)
J Immunol. 2004 Sep 15;173(6):3916-24. (PMID: 15356140)
Nat Neurosci. 2013 Sep;16(9):1211-1218. (PMID: 23872599)
Front Aging Neurosci. 2017 Jun 28;9:208. (PMID: 28701948)
J Neuroimmunol. 2016 Oct 15;299:130-138. (PMID: 27725111)
Stem Cells. 2018 Mar 25;:null. (PMID: 29575325)
Front Aging Neurosci. 2018 Feb 12;10:12. (PMID: 29483868)
Science. 2010 Nov 5;330(6005):841-5. (PMID: 20966214)
J Neuroimmunol. 2009 May 29;210(1-2):3-12. (PMID: 19269040)
Front Pharmacol. 2012 Mar 09;3:41. (PMID: 22408626)
Nat Med. 2002 Sep;8(9):963-70. (PMID: 12161747)
Mol Neurobiol. 2016 Mar;53(2):1181-94. (PMID: 25598354)
Brain. 2013 Jan;136(Pt 1):28-42. (PMID: 23365092)
Neural Plast. 2017;2017:5405104. (PMID: 28255460)
Glia. 2013 Oct;61(10):1698-711. (PMID: 23918452)
Prog Neurobiol. 2015 Aug;131:65-86. (PMID: 26067058)
J Neurosci. 2004 Mar 3;24(9):2143-55. (PMID: 14999065)
Brain Behav Immun. 2013 Aug;32:70-85. (PMID: 23454862)
Nat Neurosci. 2012 Jul 26;15(8):1078-87. (PMID: 22837038)
Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8999-9004. (PMID: 12861073)
Oncotarget. 2017 Mar 21;8(12):19855-19865. (PMID: 28423639)
Ann Neurol. 2011 Sep;70(3):374-83. (PMID: 21710619)
Annu Rev Immunol. 2014;32:367-402. (PMID: 24471431)
Nat Neurosci. 2014 Jan;17(1):131-43. (PMID: 24316888)
Trends Neurosci. 1996 Aug;19(8):312-8. (PMID: 8843599)
Neuron. 2013 Jan 9;77(1):10-8. (PMID: 23312512)
Nat Rev Neurosci. 2009 Mar;10(3):235-41. (PMID: 19229242)
Neuron. 1999 Jun;23(2):297-308. (PMID: 10399936)
J Neurosci. 2013 Jan 23;33(4):1462-85. (PMID: 23345222)
Nat Rev Immunol. 2008 Dec;8(12):958-69. (PMID: 19029990)
PLoS One. 2011;6(12):e27969. (PMID: 22205935)
Stem Cells. 2006 Mar;24(3):739-47. (PMID: 16210404)
Neuroscience. 2017 Nov 1;:null. (PMID: 29101080)
J Neuroinflammation. 2016 May 24;13(1):117. (PMID: 27220367)
J Neurosci. 2012 Feb 8;32(6):2062-85. (PMID: 22323720)
Nature. 2017 Jan 26;541(7638):481-487. (PMID: 28099414)
Nat Neurosci. 2016 Jul 26;19(8):987-91. (PMID: 27459405)
Prog Neurobiol. 1998 Oct;56(2):149-71. (PMID: 9760699)
J Exp Med. 1992 Jul 1;176(1):287-92. (PMID: 1613462)
J Neurosci. 2011 Nov 9;31(45):16064-9. (PMID: 22072657)
Brain Res. 2014 Sep 18;1581:80-8. (PMID: 24905627)

210-10-15 Marga-und-Walter-Boll Foundation; 339/2015 Universität zu Köln

Keywords: Cerebral ischemia; Hybrid microglia; M1 microglia; M2 microglia; Neuroinflammation; Neuroprotection; Stem cell-mediated regeneration

0 (Interleukin-6)
0 (Lipopolysaccharides)
0 (Tumor Necrosis Factor-alpha)
207137-56-2 (Interleukin-4)
EC 1.1.1.27 (L-Lactate Dehydrogenase)
EC 1.14.13.39 (Nitric Oxide Synthase Type II)

Date Created: 20180815 Date Completed: 20190520 Latest Revision: 20210108

20250114

PMC6090672

10.1186/s12974-018-1261-y

30103769